John Ludlow's Biography

John Ludlow, Executive Director, Regenerative Medicine, Zen-Bio, Inc.

John W. Ludlow, Ph.D, is the Executive Director of Regenerative Medicine at Zen Bio Inc. (Research Triangle Park, NC.) Prior to joining the company in 2012, John was Senior Director, Process Research and Assay Development, at Tengion Inc., a tissue engineering and regenerative medicine company (Winston-Salem, NC.) He held this position for 7 years. John also served as Senior Director, Cell Therapy Program, Vesta Therapeutics, Inc., (formerly Incara Pharmaceuticals; Research Triangle Park, NC.) for 5 years. He has developed and managed research and pre-clinical programs, initiated clinical trial sites, and directed development activities for cell therapy and tissue engineered products. He is an inventor on 4 issued patents pertaining to regenerative medicine products, and has published over 100 articles. Working closely with regulatory agencies, John has helped to ensure approval of the company’s products. John began his career as a faculty member at the University of Rochester Cancer Center (NY), where for 10 years he maintained an independently funded research laboratory training graduate students and post-doctoral fellows in the area of tumor suppressor gene expression, protein structure, and function.

Stem Cell Extracellular Vesicles as a Novel Therapy for Age-related Tendinopathy

Monday, 17 February 2020 at 17:00

Add to Calendar ▼2020-02-17 17:00:002020-02-17 18:00:00Europe/LondonStem Cell Extracellular Vesicles as a Novel Therapy for Age-related TendinopathyCirculating Biomarkers World Congress 2020 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Aging is the principal risk factor associated with tendinopathy and also contributes to a significant decrease in the ability to efficiently heal chronic tendon injury by altering the complex and highly coordinated processes required for normal resolution. In addition to increases in lifespan and a growing aging population that is remaining active, there is a concomitant rise in the prevalence of comorbidities and tendinopathy risk factors such as obesity and diabetes. These factors have led to a very high prevalence of tendon injuries in those over 60 years of age, reaching 50% of this population, resulting in decreased quality of life and an economic burden in the billions of dollars. The use of biological and stem cell therapies for tendon healing and repair have been widely investigated and have demonstrated some potential for soft tissue regeneration. Secreted extracellular vesicles (EVs), such as exosomes, are packed with potent pro-repair proteins and RNA cargos that are both cell type-specific, as well as differentially produced and secreted according to the cellular environment. We have demonstrated that mild heat shock improves the repair activity of stem cell-derived EVs in vitro and in vivo. By manipulating the cellular environment, we have found that we can alter stem cell EV production and secretion. Our results have validated an approach of manipulating the cellular environment in a closed-system bioreactor to modify the bioactive cargo of secreted EVs for improved tendon healing. This presentation will describe the further development of our pro-healing EV therapeutic approach to treat tendon injuries and tendinopathy specifically afflicting the elderly.

Add to Calendar ▼2020-02-17 00:00:002020-02-18 00:00:00Europe/LondonCirculating Biomarkers World Congress 2020Circulating Biomarkers World Congress 2020 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors